Anti-Inflammatory Action of Ivermectin Surveyed in Literature Review

Anti-Inflammatory Action of Ivermectin Surveyed in Literature Review

In clinical use since 1981 as an oral and topical medicine for a range of parasitic infection, ivermectin is on WHO’s List of Essential Medications. Anecdotally, the standard dose of 9mg used once has been correlated with some instances of “rapid clinical resolution in severe hospitalized COVID-19 [cases].” Clinical studies are underway; while ivermectin is shown to inhibit SARS-CoV-2 in vitro, but this seems to require a far higher dose than the “standard.” And this casts “doubt on  the utility of this agent as an antiviral drug in COVID-19 unless very markedly higher doses are used.” This latest ivermectin update is based on an editorial/literature review in Open Heart, an open-access journal, which is “an official journal of the British Cardiovascular Society.” The piece notes that viral-replication blocking would be less useful in late-COVID-19 with cytokine storms. Yet anecdotes point to success at this later stage. So, research should consider the idea that “ivermectin is acting as an anti-inflammatory in these cases.” This motivated the editorial search for “literature on ivermectin for anti-inflammatory actions.”

Prior Research Suggests Effectiveness

Zhang et al...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee